Axsome Therapeutics (AXSM) Stock Forecast & Price Target

Compare

2,287 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

AXSM Analyst Ratings

Strong Buy

15 Buy

0 Hold

0 Sell

Based on 15 analysts giving stock ratings to

Axsome

Therapeutics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

AXSM Stock 12 Month Forecast

Average Price Target

$175.25

▲(20.68% Upside)

Based on 15 Wall Street analysts offering 12 month price targets for Axsome Therapeutics in the last 3 months. The average price target is $175.25 with a high forecast of $202.00 and a low forecast of $148.00. The average price target represents a 20.68% change from the last price of $145.22.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"83":"$83","113":"$113","143":"$143","173":"$173","203":"$203"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":202,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$202.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":175.25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$175.25</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":148,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$148.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[83,113,143,173,203],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,149.03,153.10461538461539,157.17923076923077,161.25384615384615,165.32846153846154,169.40307692307692,173.4776923076923,177.5523076923077,181.62692307692308,185.70153846153846,189.77615384615385,193.85076923076923,197.92538461538462,{"y":202,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,149.03,151.04692307692306,153.06384615384616,155.08076923076922,157.0976923076923,159.11461538461538,161.13153846153847,163.14846153846153,165.16538461538462,167.1823076923077,169.19923076923078,171.21615384615384,173.23307692307694,{"y":175.25,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,149.03,148.95076923076923,148.87153846153845,148.7923076923077,148.71307692307693,148.63384615384615,148.55461538461537,148.47538461538463,148.39615384615385,148.31692307692308,148.2376923076923,148.15846153846155,148.07923076923078,{"y":148,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":99.08,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 55,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":84.61,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 65,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":106.46,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 75,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":127.54,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 81,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":111.67,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 77,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":112.24,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 63,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":107.66,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 58,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":102.97,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 61,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":103.02,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 57,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":123.47,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 43,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":118.57,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":134.99,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":149.03,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$202.00

Average Price Target$175.25

Lowest Price Target$148.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

David Amsellem

Piper Sandler

$148

Buy

1.91%

Upside

Reiterated

12/05/25

Axsome Therapeutics (AXSM) Receives a Buy from Piper Sandler

Graig Suvannavejh

Mizuho Securities

$202

Buy

39.10%

Upside

Reiterated

12/04/25

Mizuho Securities Sticks to Its Buy Rating for Axsome Therapeutics (AXSM)

Myles Minter

William Blair

―

Buy

―

Reiterated

11/13/25

Strategic Acquisition and Pipeline Expansion Drive Buy Rating for Axsome Therapeutics

Leonid Timashev

RBC Capital

$198

Buy

36.34%

Upside

Reiterated

11/10/25

RBC Capital Sticks to Their Buy Rating for Axsome Therapeutics (AXSM)

Ram Selvaraju

H.C. Wainwright

$180→$185

Buy

27.39%

Upside

Reiterated

11/07/25

Axsome Therapeutics price target raised to $185 from $180 at H.C. WainwrightAxsome Therapeutics price target raised to $185 from $180 at H.C. Wainwright

Joon Lee

Truist Financial

―

Buy

―

Reiterated

11/04/25

Axsome Therapeutics (AXSM) Receives a Rating Update from a Top Analyst

Ami Fadia

Needham

$150→$154

Buy

6.05%

Upside

Assigned

11/04/25

Axsome Therapeutics: Strong Financial Performance and Strategic Advancements Drive Buy RatingWe expect the stock to be up today on strong commercial performance on both Auvelity and Sunosi.

Sean Laaman

Morgan Stanley

$194→$196

Buy

34.97%

Upside

Reiterated

11/04/25

Axsome Therapeutics price target raised to $196 from $194 at Morgan StanleyAxsome Therapeutics price target raised to $196 from $194 at Morgan Stanley

Benjamin Burnett

Wells Fargo

$163→$157

Buy

8.11%

Upside

Reiterated

11/04/25

Axsome Therapeutics price target lowered to $157 from $163 at Wells FargoAxsome Therapeutics price target lowered to $157 from $163 at Wells Fargo

Jason Gerberry

Bank of America Securities

$176→$178

Buy

22.57%

Upside

Reiterated

11/03/25

Axsome Therapeutics (AXSM) Receives a Buy from Bank of America Securities

Joseph Thome

TD Cowen

$190

Buy

30.84%

Upside

Reiterated

11/03/25

Axsome Therapeutics' Strong Market Position and Growth Potential Highlighted by Impressive Auvelity Performance and Strategic ExpansionWe do not believe that investors had significant expectations above consensus for Auvelity into the update today and product uptake continues to outpace the broader antidepressant market; thus, we expect the slight beat will come as a nice update for investors. Uptake for Auvelity continues to look solid, with average wkly NBRx numbers up ~35% since the sales force expansion earlier this year, and up ~50% in the PCP segment in particular, which we and mgmt see as a key growth driver for the product. Overall, we see Auvelity as poised for continued growth in the near-term as the company continues to penetrate the large PCP segment of the prescriber base, and we continue to model ~$2.5B in peak sales in MDD.

Ashwani Verma

UBS

$144→$163

Buy

12.24%

Upside

Reiterated

10/16/25

UBS Remains a Buy on Axsome Therapeutics (AXSM)Axsome Therapeutics Inc (AXSM.O, Buy, $144 --> $163) Focus on Auvelity ADA filing: Takeaways from our discussion with mgmt. 3Q preview (Ashwani Verma) Report

Marc Goodman

Leerink Partners

―

Buy

―

Reiterated

10/07/25

Leerink Partners Sticks to Its Buy Rating for Axsome Therapeutics (AXSM)

Madison Elsaadi

B. Riley Securities

$179

Buy

23.26%

Upside

Initiated

10/01/25

Axsome Therapeutics initiated with a Buy at B. RileyAxsome Therapeutics initiated with a Buy at B. Riley

Pete Stavropoulos

Cantor Fitzgerald

$153

Buy

5.36%

Upside

Reiterated

09/15/25

Cantor Fitzgerald Reaffirms Their Buy Rating on Axsome Therapeutics (AXSM)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

David Amsellem

Piper Sandler

$148

Buy

1.91%

Upside

Reiterated

12/05/25

Axsome Therapeutics (AXSM) Receives a Buy from Piper Sandler

Graig Suvannavejh

Mizuho Securities

$202

Buy

39.10%

Upside

Reiterated

12/04/25

Mizuho Securities Sticks to Its Buy Rating for Axsome Therapeutics (AXSM)

Myles Minter

William Blair

―

Buy

―

Reiterated

11/13/25

Strategic Acquisition and Pipeline Expansion Drive Buy Rating for Axsome Therapeutics

Leonid Timashev

RBC Capital

$198

Buy

36.34%

Upside

Reiterated

11/10/25

RBC Capital Sticks to Their Buy Rating for Axsome Therapeutics (AXSM)

Ram Selvaraju

H.C. Wainwright

$180→$185

Buy

27.39%

Upside

Reiterated

11/07/25

Axsome Therapeutics price target raised to $185 from $180 at H.C. WainwrightAxsome Therapeutics price target raised to $185 from $180 at H.C. Wainwright

Joon Lee

Truist Financial

―

Buy

―

Reiterated

11/04/25

Axsome Therapeutics (AXSM) Receives a Rating Update from a Top Analyst

Ami Fadia

Needham

$150→$154

Buy

6.05%

Upside

Assigned

11/04/25

Axsome Therapeutics: Strong Financial Performance and Strategic Advancements Drive Buy RatingWe expect the stock to be up today on strong commercial performance on both Auvelity and Sunosi.

Sean Laaman

Morgan Stanley

$194→$196

Buy

34.97%

Upside

Reiterated

11/04/25

Axsome Therapeutics price target raised to $196 from $194 at Morgan StanleyAxsome Therapeutics price target raised to $196 from $194 at Morgan Stanley

Benjamin Burnett

Wells Fargo

$163→$157

Buy

8.11%

Upside

Reiterated

11/04/25

Axsome Therapeutics price target lowered to $157 from $163 at Wells FargoAxsome Therapeutics price target lowered to $157 from $163 at Wells Fargo

Jason Gerberry

Bank of America Securities

$176→$178

Buy

22.57%

Upside

Reiterated

11/03/25

Axsome Therapeutics (AXSM) Receives a Buy from Bank of America Securities

Joseph Thome

TD Cowen

$190

Buy

30.84%

Upside

Reiterated

11/03/25

Ashwani Verma

UBS

$144→$163

Buy

12.24%

Upside

Reiterated

10/16/25

Marc Goodman

Leerink Partners

―

Buy

―

Reiterated

10/07/25

Leerink Partners Sticks to Its Buy Rating for Axsome Therapeutics (AXSM)

Madison Elsaadi

B. Riley Securities

$179

Buy

23.26%

Upside

Initiated

10/01/25

Axsome Therapeutics initiated with a Buy at B. RileyAxsome Therapeutics initiated with a Buy at B. Riley

Pete Stavropoulos

Cantor Fitzgerald

$153

Buy

5.36%

Upside

Reiterated

09/15/25

Cantor Fitzgerald Reaffirms Their Buy Rating on Axsome Therapeutics (AXSM)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Axsome Therapeutics

1 Month

xxx

Success Rate

20/31 ratings generated profit

Average Return

+13.57%

reiterated a xxx

rating 28 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 64.52% of your transactions generating a profit, with an average return of +13.57% per trade.

3 Months

xxx

Success Rate

18/25 ratings generated profit

Average Return

+13.90%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 72.00% of your transactions generating a profit, with an average return of +13.90% per trade.

1 Year

Leonid TimashevRBC Capital

Success Rate

21/21 ratings generated profit

Average Return

+37.37%

reiterated a buy rating last month

Copying Leonid Timashev's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +37.37% per trade.

2 Years

xxx

Success Rate

33/33 ratings generated profit

Average Return

+76.15%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +76.15% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

AXSM Analyst Recommendation Trends

Rating

Aug 25

Sep 25

Oct 25

Nov 25

Dec 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, AXSM has received 21 Buy Ratings, 3 Hold Ratings, and 0 Sell Ratings. AXSM average Analyst price target in the past 3 months is 175.25.

Each month's total comprises the sum of three months' worth of ratings.

AXSM Financial Forecast

AXSM Earnings Forecast

Next quarter’s earnings estimate for AXSM is -$0.72 with a range of -$1.16 to -$0.38. The previous quarter’s EPS was -$0.94. AXSM beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year AXSM has Performed in-line its overall industry.

AXSM Sales Forecast

Next quarter’s sales forecast for AXSM is $187.46M with a range of $180.70M to $195.20M. The previous quarter’s sales results were $170.99M. AXSM beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year AXSM has Performed in-line its overall industry.

AXSM Stock Forecast FAQ

What is AXSM’s average 12-month price target, according to analysts?

Based on analyst ratings, Axsome Therapeutics Inc’s 12-month average price target is 175.25.

What is AXSM’s upside potential, based on the analysts’ average price target?

Axsome Therapeutics Inc has 20.68% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is AXSM a Buy, Sell or Hold?

Axsome Therapeutics Inc has a consensus rating of Strong Buy which is based on 15 buy ratings, 0 hold ratings and 0 sell ratings.

What is Axsome Therapeutics Inc’s price target?

The average price target for Axsome Therapeutics Inc is 175.25. This is based on 15 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $202.00 ,the lowest forecast is $148.00. The average price target represents 20.68% Increase from the current price of $145.22.

What do analysts say about Axsome Therapeutics Inc?

Axsome Therapeutics Inc’s analyst rating consensus is a Strong Buy. This is based on the ratings of 15 Wall Streets Analysts.

How can I buy shares of AXSM?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Axsome Therapeutics (AXSM) Stock Forecast & Price Target

AXSM Analyst Ratings

AXSM Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Axsome Therapeutics

AXSM Analyst Recommendation Trends

AXSM Financial Forecast

AXSM Earnings Forecast

AXSM Sales Forecast

AXSM Stock Forecast FAQ

Detailed List of Analyst Forecasts